Liver Diseases Therapeutics Market Analysis By Product (Antiviral Drugs, Vaccines, Chemotherapy, Targeted Therapy, Immunosuppressants, Immunoglobulins, Corticosteroids), And Segment Forecasts To 2022

Table of Content

Chapter 1. Methodology and Scope
                    1.1. Research methodology
                    1.2. Research scope & assumption
                    1.3. List of data sources
Chapter 2. Executive Summary
                    2.1. Liver diseases therapeutics - Industry Summary and Key Buying Criteria, 2012 - 2022
Chapter 3. Liver diseases therapeutics Industry Outlook
                    3.1. Liver diseases therapeutics market segmentation
                    3.2. Liver diseases therapeutics market size and growth prospects, 2012-2022
                    3.3. Liver diseases therapeutics market dynamics
                       3.3.1. Market driver analysis
                       3.3.2. Market restraint analysis
                    3.4. Key opportunities prioritized
                    3.5. Industry analysis - Porter's
                    3.6. Liver diseases therapeutics: Company market share, 2014
                    3.7. Liver diseases therapeutics market PESTEL analysis, 2014
Chapter 4. Liver diseases therapeutics Product Outlook
                    4.1. Liver diseases therapeutics market share by product, 2014 & 2022
                    4.2. Anti-Viral Drugs market estimates and forecasts, 2012 - 2022 (USD Million)
                    4.3. Vaccines market estimates and forecasts, 2012 - 2022 (USD Million)
                    4.4. Chemotherapy market estimates and forecasts, 2012 - 2022 (USD Million)
                    4.5. Targeted therapy market estimates and forecasts, 2012 - 2022 (USD Million)
                    4.6. Immunosuppressants market estimates and forecasts, 2012 - 2022 (USD Million)
                    4.7. Immunoglobulins market estimates and forecasts, 2012 - 2022 (USD Million)
                    4.8. Corticosteroids market estimates and forecasts, 2012 - 2022 (USD Million)
Chapter 5. Liver diseases therapeutics Regional Outlook
                    5.1. North America
                       5.1.1. North America market, by product, 2012 - 2022 (USD Million)
                    5.2. Europe
                       5.2.1. Europe market, by product, 2012 - 2022 (USD Million)
                    5.3. Asia Pacific
                       5.3.1. Asia Pacific market, by product, 2012 - 2022 (USD Million)
                    5.4. RoW
                       5.4.1. RoW market, by product, 2012 - 2022 (USD Million)
Chapter 6. Competitive Landscape
                    6.1. Abbott Laboratories
                       6.1.1. Company Overview
                       6.1.2. Financial Performance
                       6.1.3. Product Benchmarking
                       6.1.4. Strategic Initiatives
                    6.2. Astellas Pharma Inc.
                       6.2.1. Company Overview
                       6.2.2. Financial Performance
                       6.2.3. Product Benchmarking
                       6.2.4. Strategic Initiatives
                    6.3. Bristol-Mayers Squibb
                       6.3.1. Company Overview
                       6.3.2. Financial Performance
                       6.3.3. Product Benchmarking
                       6.3.4. Strategic Initiatives
                    6.4. Gilead Sciences
                       6.4.1. Company Overview
                       6.4.2. Financial Performance
                       6.4.3. Product Benchmarking
                       6.4.4. Strategic Initiatives
                    6.5. GlaxoSmithKline Pharmaceuticals Ltd
                       6.5.1. Company Overview
                       6.5.2. Financial Performance
                       6.5.3. Product Benchmarking
                       6.5.4. Strategic Initiatives
                    6.6. F. Hoffmann-La Roche Ltd
                       6.6.1. Company Overview
                       6.6.2. Financial Performance
                       6.6.3. Product Benchmarking
                       6.6.4. Strategic Initiatives
                    6.7. Merck & Co. Inc
                       6.7.1. Company Overview
                       6.7.2. Financial Performance
                       6.7.3. Product Benchmarking
                       6.7.4. Strategic Initiatives
                    6.8. Novartis AG
                       6.8.1. Company Overview
                       6.8.2. Financial Performance
                       6.8.3. Product Benchmarking
                       6.8.4. Strategic Initiatives
                    6.9. Sanofi S.A
                       6.9.1. Company Overview
                       6.9.2. Financial Performance
                       6.9.3. Product Benchmarking
                       6.9.4. Strategic Initiatives
                    6.10. Pfizer Inc.
                       6.10.1. Company Overview
                       6.10.2. Financial Performance
                       6.10.3. Product Benchmarking
                       6.10.4. Strategic Initiatives
                    6.11. Takeda Pharmaceuticals
                       6.11.1. Company Overview
                       6.11.2. Financial Performance
                       6.11.3. Product Benchmarking
                       6.11.4. Strategic Initiatives
                    6.12. Valeant Pharmaceuticals
                       6.12.1. Company Overview
                       6.12.2. Financial Performance
                       6.12.3. Product Benchmarking
                       6.12.4. Strategic Initiatives
                    6.13. Watson Pharmaceuticals
                       6.13.1. Company Overview
                       6.13.2. Financial Performance
                       6.13.3. Product Benchmarking
                       6.13.4. Strategic Initiatives

List of Tables

1. Liver diseases therapeutics– Industry Snapshot
2. Liver diseases therapeutics market, by Product, 2012 - 2022 (USD million)
3. Liver diseases therapeutics market, by Region, 2012 - 2022 (USD million)
4. Liver diseases therapeutics market - Key Market Drivers Analysis
5. Liver diseases therapeutics market - Key Market Restraints Analysis
6. North America Liver diseases therapeutics market , by Product, 2012 - 2022 (USD million)
7. Europe Liver diseases therapeutics market, by Product, 2012 - 2022 (USD million)
8. Asia Pacific Liver diseases therapeutics market, by Product, 2012 - 2022 (USD million)
9. RoW Liver diseases therapeutics market, by Product, 2012 - 2022 (USD million)

List of Figures

1. Liver diseases therapeutics market segmentation
2. Global Liver diseases therapeutics market revenue, 2012 - 2022
3. Liver diseases therapeutics market dynamics
4. Key Opportunities Prioritized
5. Liver diseases therapeutics market Analysis - Porter's
6. Liver diseases therapeutics market Analysis - PESTEL Analysis
7. Global Liver diseases therapeutics market , By product, 2012 - 2022 (USD million)
8. Anti-Viral Drugs Market, 2012 - 2022 (USD million)
9. Vaccines Market, 2012 - 2022 (USD million)
10. Chemotherapy Market, 2012 - 2022 (USD million)
11. Targeted therapy Market, 2012 - 2022 (USD million)
12. Immunosuppressants Market, 2012 - 2022 (USD million)
13. Immunoglobulins Market, 2012 - 2022 (USD million)
14. Corticosteroids Market, 2012 - 2022 (USD million)
15. Global Liver diseases therapeutics market , By Region 2012 to 2022 (USD million)
16. North America Market, by Product 2012 to 2022 (USD million)
17. Europe Market, by Product 2012 to 2022 (USD million)
18. Asia Pacific Market, by Product 2012 to 2022 (USD million)
19. RoW Market, by Product 2012 to 2022 (USD million)